Today's BioPharma 07/02/09

Slow day on Wall St. Back to a decline. Futures are shaky. It has been a bad couple of weeks for Wall Street as the markets have retracted due to High Unemployment rates, I too am unemployed so I understand. But with a decline in the market, it is a good time to buy that next big race winner!!!

Seriously, buy low these days and invest wisely. Don't buy into the hype surrounding big news, after big news hits, purchase the stocks on a limit order, for a nice discounted rate. Take your time with your picks and be patient. It's tough but you have to do it. Hopefully you won't have a Biogen Idec stock that rises sharply only to fall considerably due to deaths from their MS drug. Or others like Bayer, Schering Plough, Merck, all the big names have had considerable losses due to big time lawsuits that must be battled out in court.

But thats the time to buy. When it drops like that, Buy it. Its hard to do but this is the nature of the beast.

Okay, in todays market we are watching closely the FDA calender for the following stocks, HEB and SPPI. Both are due anyday now with July second as the date for Spectrum's FDA calendar is for Zevalin® (ibritumomab tiuxetan, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin's Lymphoma. HEB has a Chronic Fatigue Syndrome med that might or might not get approved. Hemispherx BioPharma, Inc(Public, AMEX:HEB)

About Hemispherx Biopharma, Inc.
Hemispherx Biopharma, Inc., headquartered in Philadelphia, Pennsylvania, is a biopharmaceutical company dedicated to treating and preventing chronic viral and immune-based disorders through the development and manufacturing of compounds that enhance the natural immune system of the human body. The Company's flagship products include Alferon N Injection and the experimental immunotherapeutics Ampligen and Oragens . Its platform technology includes large and small agents for potential treatment of various chronic viral infections. Ampligen , is a new class of specifically-configured ribonucleic acid (RNA) compounds targeted at such important diseases as Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME), HIV, Hepatitis B, Hepatitis C, and cancers including kidney cancer and metastatic malignant melanoma. Alferon N Injection (interferon alfa-n3, human leukocyte derived) is a highly purified, natural source, glycosylated, multi-species alpha interferon product, composed of eight forms of high-purified alpha interferon. It is the only natural source, multi-species alfa interferon currently sold in the United States and is also approved for sale in certain other countries, including Mexico, Germany, Hong Kong and Singapore. Alferon N Injection is the company's registered trademark for it's injectible formulation or natural alpha interferon approved by the FDA for the treatment of genital HPV (refractory condylomata acuminata). ...

Okay so with that said on forward to today's stock focus which is, Emisphere (EMIS) is an emerging bio-pharma company specializing in the development of a drug delivery technology platform for the oral administration of therapeutic compounds which are either poorly absorbed or must be given through alternative routes such as injections.

This article can be read on Seeking Alpha, with Mike Havrilla, the dudes on point and has expensive FDA calendars which he usually keeps most of them available for public view.

So Check out EMIS Emisphere and decide for yourself, this is a must buy!

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.